Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.72 USD
0.00 (0.00%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FBIO 1.72 0.00(0.00%)
Will FBIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBIO
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
FBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
Other News for FBIO
Mustang Bio Announces Pricing of $4 Million Public Offering
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Avenue Therapeutics Announces Reverse Stock Split
12 Health Care Stocks Moving In Wednesday's After-Market Session